Strategies in antiepileptic drug development: is rational drug design superior to random screening and structural variation?
- 1 February 1994
- journal article
- review article
- Published by Elsevier BV in Epilepsy Research
- Vol. 17 (2), 95-134
- https://doi.org/10.1016/0920-1211(94)90012-4
Abstract
No abstract availableKeywords
This publication has 94 references indexed in Scilit:
- Characterization of the anticonvulsant properties of F-721Epilepsy Research, 1993
- Effects of the antiepileptic drug valproate on metabolism and function of inhibitory and excitatory amino acids in the brainNeurochemical Research, 1993
- Characterisation of [3H]gabapentin binding to a novel site in rat brain: homogenate binding studiesEuropean Journal of Pharmacology: Molecular Pharmacology, 1993
- Studies on 2-n-propyl-2(E)-pentenoate (Δ2(E)-valproate) in manInternational Journal of Clinical Pharmacy, 1992
- Pharmacological, toxicological and neurochemical effects of Δ2(E)-valproate in animalsInternational Journal of Clinical Pharmacy, 1992
- Single-dose tolerance and pharmacokinetics of 2-n-propyl-2(E)-pentenoate (Δ2(E)-valproate) in healthy male volunteersInternational Journal of Clinical Pharmacy, 1992
- Lamotrigine in primary generalised epilepsyThe Lancet, 1992
- New class of hallucinogens: GABA-enhancing agentsDrug Development Research, 1990
- Blockade of N-methyl-D-aspartate induced convulsions by 1-aminocyclopropanecarboxylatesLife Sciences, 1989
- Conversion of orally administered 2-n.pentylaminoacetamide into glycinamide and glycine in the rat brainLife Sciences, 1983